Janssen’s Stelara Gets FDA Approval As Novel Psoriatic Arthritis Treatment

The FDA has approved Janssen Biotech’s Stelara for use in adults 18 or older with active psoriatic arthritis. The protein antagonist is the first treatment approved for the “devastating and complex disease” since the introduction of TNF-blockers more than a decade ago, said Jerome Boscia, the company’s head of immunology development, Sept. 23.
Washington Drug Letter